Luminal B breast cancer: patterns of recurrence and clinical outcome

被引:79
作者
Li, Zhi-hua [1 ]
Hu, Ping-hua [1 ]
Tu, Jian-hong [2 ]
Yu, Ni-si [3 ]
机构
[1] Third Hosp Nanchang City, Key Lab Breast Dis Jiangxi Prov, Prevent & Cure Ctr Breast Dis, Nanchang 330009, Jiangxi, Peoples R China
[2] JiangXi Breast Specialist Hosp, Hosp Nanchang City 3, Dept Pathol, Nanchang 330009, Jiangxi, Peoples R China
[3] Jiangxi Tradit Chinese Med Univ, Affiliated Hosp, Dept Gynaecol, Nanchang 330006, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
luminal B subtype; breast cancer; recurrence pattern; prognosis; INTERNATIONAL EXPERT CONSENSUS; GENE-EXPRESSION PROFILES; LOCOREGIONAL RECURRENCE; RANDOMIZED-TRIAL; PRIMARY THERAPY; RISK-FACTORS; SUBTYPES; SURVIVAL; TUMOR; CHEMOTHERAPY;
D O I
10.18632/oncotarget.11344
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, most studies on breast cancer relapse and metastasis have focused on non-luminal breast cancers (including the basal-like and HER-2 subtypes) because of their poor prognosis. However, the luminal B subtype is more common, but this type has not been investigated as thoroughly. In the current study, we collected data on 258 patients with luminal-B breast cancer patients with recurrence and metastasis served as the observation group, and 189 patients with non-luminal breast cancer during the same period served as the control group. This study aimed to investigate the pattern of recurrence and clinical outcome after follow-up treatment for luminal B breast cancer. We found a higher proportion of local recurrence and single bone metastasis in patients with luminal B breast cancer than in patients in the non-luminal groups. The risk of recurrence and metastasis in patients with luminal B breast cancer during a 2- to 5-year period and after 5 years was still present, but the risk in patients with non-luminal breast cancers had obviously decreased during the same period. Patients with luminal B breast cancer with recurrence or/and metastasis had a better prognosis after reasonable treatment. The recurrence patterns and clinical outcomes of patients with luminal B breast cancer according to HER2 status were also different, to some degree. These results are of potential clinical relevance especially for the monitoring of clinical prognosis and targeted therapy intervention for luminal B breast cancer.
引用
收藏
页码:65024 / 65033
页数:10
相关论文
共 43 条
  • [1] Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
    Ades, Felipe
    Zardavas, Dimitrios
    Bozovic-Spasojevic, Ivana
    Pugliano, Lina
    Fumagalli, Debora
    de Azambuja, Evandro
    Viale, Giuseppe
    Sotiriou, Christos
    Piccart, Martine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2794 - +
  • [2] Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
    Aebi, Stefan
    Gelber, Shari
    Anderson, Stewart J.
    Lang, Istvan
    Robidoux, Andre
    Martin, Miguel
    Nortier, Johan W. R.
    Paterson, Alexander H. G.
    Rimawi, Mothaffar F.
    Canada, Jose Manuel Baena
    Thuerlimann, Beat
    Murray, Elizabeth
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Price, Karen N.
    Coates, Alan S.
    Gelber, Richard D.
    Rastogi, Priya
    Wolmark, Norman
    Wapnir, Irene L.
    [J]. LANCET ONCOLOGY, 2014, 15 (02) : 156 - 163
  • [3] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
    Albain, Kathy S.
    Barlow, William E.
    Shak, Steven
    Hortobagyi, Gabriel N.
    Livingston, Robert B.
    Yeh, I-Tien
    Ravdin, Peter
    Bugarini, Roberto
    Boehner, Frederick L.
    Davidson, Nancy E.
    Sledge, George W.
    Winer, Eric P.
    Hudis, Clifford
    Ingle, James N.
    Perez, Edith A.
    Pritchard, Kathleen I.
    Shepherd, Lois
    Gralow, Julie R.
    Yoshizawa, Carl
    Allred, D. Craig
    Osborne, C. Kent
    Hayes, Daniel F.
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 55 - 65
  • [4] Patterns of distant metastasis in Chinese women according to breast cancer subtypes
    Wu, San-Gang
    Sun, Jia-Yuan
    Yang, Li-Chao
    Tang, Li-Ying
    Wang, Xue
    Chen, Xue-Ting
    Liu, Gui-Hua
    Lin, Huan-Xin
    Lin, Qin
    He, Zhen-Yu
    [J]. ONCOTARGET, 2016, 7 (30) : 47975 - 47984
  • [5] Luminal-B breast cancer and novel therapeutic targets
    Ben Tran
    Bedard, Philippe L.
    [J]. BREAST CANCER RESEARCH, 2011, 13 (06)
  • [6] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
    Cheang, Maggie C. U.
    Chia, Stephen K.
    Voduc, David
    Gao, Dongxia
    Leung, Samuel
    Snider, Jacqueline
    Watson, Mark
    Davies, Sherri
    Bernard, Philip S.
    Parker, Joel S.
    Perou, Charles M.
    Ellis, Matthew J.
    Nielsen, Torsten O.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10): : 736 - 750
  • [7] Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy
    Chen, Sheng
    Huang, Liang
    Chen, Can-Ming
    Shao, Zhi-Ming
    [J]. ONCOTARGET, 2015, 6 (20) : 18174 - 18182
  • [8] Clarke M, 1998, LANCET, V351, P1451
  • [9] Locoregionally recurrent breast cancer: incidence, risk factors and survival
    Clemons, M
    Danson, S
    Hamilton, T
    Goss, P
    [J]. CANCER TREATMENT REVIEWS, 2001, 27 (02) : 67 - 82
  • [10] Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics
    Colzani, E.
    Johansson, A. L. V.
    Liljegren, A.
    Foukakis, T.
    Clements, M.
    Adolfsson, J.
    Hall, P.
    Czene, K.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1378 - 1384